Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022
August 12, 2022 at 07:00 am EDT
Share
Rapid Micro Biosystems, Inc. revises earnings guidance for the full year 2022. For the year, the company updated its prior revenue outlook to at least $17.0 million. The Company's lowered guidance reflects expectations for fewer systems placements in fiscal year 2022 as it continues to ramp its commercial team and optimize its commercial execution as well as macro-economic uncertainty that is expected to persist through the second half of the year.
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.